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Knowledge of the full target space of bioactive sub-
stances, approved and investigational drugs as well
as chemical probes, provides important insights
into therapeutic potential and possible adverse ef-
fects. The existing compound-target bioactivity
data resources are often incomparable due to non-
standardized and heterogeneous assay types and
variability in endpoint measurements. To extract
higher value from the existing and future compound
target-profiling data, we implemented an open-data
web platform, named Drug Target Commons (DTC),
which features tools for crowd-sourced compound-
target bioactivity data annotation, standardization,
curation, and intra-resource integration. We demon-
strate the unique value of DTC with several examples
related to both drug discovery and drug repurposing
applications and invite researchers to join this com-
munity effort to increase the reuse and extension of
compound bioactivity data.
INTRODUCTION
Mapping the full spectrum of potential interactions between
compounds and their targets, including both intended or ‘‘pri-
mary targets’’ as well as unintended secondary or ‘‘off-targets’’,
is a critical part of most drug discovery and development efforts,
not only enabling exploration of the therapeutic potential of these
chemical agents but also better understanding andmanagement
of their possible adverse reactions prior to clinical testing. Accu-
mulating data show that most drugs bind tomore than one target
molecule within a biologically relevant affinity range (Santos
et al., 2017). For instance, most kinase inhibitors bind to the224 Cell Chemical Biology 25, 224–229, February 15, 2018 ª 2017 Th
This is an open access article under the CC BY license (http://creativeconserved ATP-binding pocket of several or many distinct
protein kinase domains that share sequence and structural
similarity, leading to target promiscuity and a broad range
of polypharmacological effects (Davis et al., 2011). Systems-
wide compound-target interaction networks are therefore
necessary to fully understand themode of action of such promis-
cuous compounds, as well as to extend therapeutic uses of
both approved and abandoned drugs, i.e., drug repurposing
(Pemovska et al., 2015).
Efforts have been made to collect and curate quantitative
compound-target interaction data, covering both active and
inactive endpoints from various high- and low-throughput
target-profiling experiments (Hersey et al., 2015; Santos et al.,
2017; Wang et al., 2017). The diversity of specific profiling
bioassays and approaches in drug discovery often leads to a
high degree of data heterogeneity, commonly arising from the
use of different experimental assays and bioactivity endpoints,
as well as from differing detection technologies and endpoint
measurements. Such non-standardized and heterogeneous
experimental factors pose challenges for the comparison and
integration of these bioactivity data resources, especially when
using them to interpret and mine phenotypic profiling data for
drug discovery and drug repurposing applications, an area of
research that has gained significant traction in recent years
(Arrowsmith et al., 2015; Schreiber et al., 2015; Plowright et al.,
2017; Licciardello et al., 2017; Corsello et al., 2017).
To address these challenges, we implemented a web-based,
open-access platform, called Drug Target Commons (DTC,
https://drugtargetcommons.fimm.fi/), to initiate a community-
driven crowd-sourcing effort to collectively extract, integrate,
annotate, and standardize quantitative compound-target bioac-
tivity data from the literature and other database sources
(Figure 1). DTC implements a number of unique features
including: (1) an interactive web interface enabling end users to
not only upload new data from experiments or literature but
also to participate in the data annotation and curation, together
with the committed data approvers; (2) a specifically adaptede Authors. Published by Elsevier Ltd.
commons.org/licenses/by/4.0/).
Figure 1. Schematics of the DTC Platform (Open-Access Database and Web Application)
The web-based platform enables the user community to take part in crowd-sourced data extraction, annotation, and curation, as well as in using and analyzing
comprehensive and standardized compound-target interaction profiles. The community-driven effort aims to provide maximally high-quality and reproducible
bioactivity profiles and related information that will be fed back and cross-referenced to the original data sources, therefore supplementing and enhancing the
coverage and annotation of existing drug/target data resources through the crowd-sourcing initiative. Processing errors and inconsistencies in the experimental
data can be minimized via open discussions, enabled by the web interface, and only the most reliable bioactivity data will be released for end users through
regular updates under the Creative Commons License.compound-target bioactivity assay annotation and data curation
procedure to provide more informative target profiles, making it
possible to sort out inconsistencies between profiling studies
that use differing assay types and endpoints; and (3) high-quality
and comprehensive target profiles, which include not only
the primary and secondary targets but also disease- or drug-
response-related mutant targets, hence capturing the whole
spectrum of potential target potencies. Comparedwith the exist-
ing data resources, the open-data environment and crowd-
sourcing curation ensures that themost up-to-date experimental
data for compound-target interactions will be sufficiently anno-
tated and cross-checked before being approved and deposited
into the DTC database (Table S1).
Bioassay Annotation Explains Part of the Heterogeneity
in Bioactivity Data
Differing experimental assays contribute to heterogeneous
and irreproducible bioactivity data. For example, biochemicalassays typically generate higher potency numbers than cell-
based assays, especially for compounds that compete for
binding with natural ligands or enzyme cofactors, such as
ATP-competitive kinase inhibitors. However, large differences
between biochemical and cellular potencies may also suggest
that the compound does not penetrate the cell membrane,
that it has undesirable protein-binding activities, or that it is
not metabolically stable in cellular environments. To facilitate
the standardization of bioassay annotation, we implemented
a simplified version of the bioassay ontology (BAO) (Abeyru-
wan et al., 2014), termed mBAO (micro bioassay ontology),
which conforms to the MIABE (minimum information about a
bioactive entity) guidelines (Orchard et al., 2011) for describing
compound-target bioactivities (Table S2). Compared with
the original BAO, the simplified mBAO annotation allows
the data curators to extract the assay information relatively
quickly from the method descriptions of published literature
(Figures S1 and S2).Cell Chemical Biology 25, 224–229, February 15, 2018 225
Figure 2. Bioassay Annotations Explain
Heterogeneity in Bioactivity Data
(A) 74 bioactivity data points for the gefitinib-EGFR
drug-target pair prior to assay annotation.
(B) The mBAO annotation process revealed that the
major source of the variation was driven by the
assay type (x axis), and further variation can be
attributed to the detection technique and assay
formats (colors and shapes). The low potency
outliers originated from kinase assays run at very
high ATP concentrations.
(C) 78 bioactivity data points for the celecoxib-
COX2 drug-target pair before assay annotations.
(D) A clear distinction was observed in the assays
performed ex vivo (human blood), compared with
recombinant proteins (x axis). Further variation in
the bioactivities arises from the specific target
sources.
See also Figures S1 and S2.As a proof of concept, we performed three rounds of data
extraction and annotation processing with the DTC platform.
These test rounds have already produced an extensive and stan-
dardized open-data resource that spans a broad spectrum of
compound and target classes (Figures S3 and S4; Table S3).
We initiated the mBAO annotation process based on the bioac-
tivity assays that have already been deposited in ChEMBL,
currently themost comprehensive, public-domain, andmanually
curated bioactivity database (Gaulton et al., 2017). These initial
test rounds have resulted so far in 187,600 fully annotated
bioactivity data points among 4,082 chemical compounds and
across 528 distinct protein targets, with specific focus on kinase
targets.226 Cell Chemical Biology 25, 224–229, February 15, 2018As a first specific example, we focused
on gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor
approved for treatment of patients with
non-small-cell lung cancer. The available,
nominally comparable gefitinib/EGFR
interaction affinity data points (which in
the initial release of DTC largely come
from the data in ChEMBL) were spread
out over a 10,000-fold concentration
range (Figure 2A). However, the mBAO
annotation enabled a better understand-
ing of the heterogeneity in the gefitinib/
EGFR bioactivity values (Figure 2B; see
Figure S2 for examples). Specifically, the
observed variability in the bioactivity
data points was due primarily to func-
tional assays that used different assay
formats and detection technologies,
whereas the binding assays showed
more consistent potency values (Fig-
ure 2B). The extreme outliers in the func-
tional assays originated from various
detection methods. Of note, publication
or deposition errors are beyond the scope
of any assay annotation and may explaina portion of the remaining outlier data points (Kruger and Over-
ington, 2012).
As a second case example, we carefully annotated a new set
of bioactivities reported between the non-steroidal anti-inflam-
matory drug, celecoxib, and its primary target cyclooxygenase
2 (COX-2; gene symbol PTGS2). In doing so, we observed that
adding information about the source of the target protein is
essential for explaining the data heterogeneity (Figure 2C).
Notably, assays using purified recombinant protein exhibited
more than 10-fold higher potency than those measuring enzy-
matic activity in cellular extracts (Figure 2D). One explanation
for the differing readouts may be that the high protein-binding
propensity of celecoxib reduces its free concentration in the
Figure 3. Compounds with Differential Potency against ABL1 (T315I)
(A) A set of 25 compounds that showed potency toward phosphorylated-ABL1 (T315I), based on the current DTC database. Bubbles mark the potency class
(based on half maximal inhibitory concentration [IC50] in nM) of these compounds toward ABL1 (T315I), wild-type ABL1, and Aurora kinase B (AURKB), as an
estimate of the potential therapeutic window. The structural similarity of the compounds is visualized as a dendrogram (constructed with the C-SPADE web tool
available at http://cspade.fimm.fi; Ravikumar et al., 2017). The gray-shaded part marks candidate compounds, KW-2449 and to a lesser extent TAE-684, that are
structurally similar to axitinib (an ABL1 [T315I] inhibitor), and show similar differential selectivity toward ABL1 (T315I).
(B) Ba/F3 cells stably expressing BCR-ABL1 (T315I) were used for experimental validation, with compound concentrations on the x axis and the viability readout
on the y axis (mean and SD errors calculated based on three ormore replicates). As expected, the positive control axitinib had a higher potency toward BCR-ABL1
(T315I)-driven cells, compared with BCR-ABL1 wild-type-driven cells; similarly, KW-2449 showed a slightly higher potency toward ABL1 (T315I) compared with
BCR-ABL1 wild-type. The potency of TAE-684 was actually higher toward BCR-ABL1 wild-type than toward ABL1 (T315I) in the cell-based validation,
demonstrating the importance of further pre-clinical evaluations before entering the drug optimization or repurposing phases.more heterogeneous cell-extract assays, and therefore results in
a perceived lower target potency (Paulson et al., 1999), but there
may also be other factors such as metabolic stability that
contribute to this difference. This example emphasizes the
importance of deep enough assay annotation for interpreting
the heterogeneous bioactivity profiles.
DTC Provides a High-Quality Knowledge Base to
Facilitate Drug Repositioning
Among the 4,082 compounds we have annotated so far, we
found interesting selectivity patterns that may help identify
drug repurposing opportunities. Despite the high number of
bioactivity data for some well-studied compounds, such as da-
satinib, bosutinib, and staurosporine, each with more than
1,000 unique bioactivity records (Figure S5), the size of the po-
tential target space is much smaller, with an average one potent
target per compound (STAR Methods). When searching for
potent inhibitors against given proteins, FLT3, AURKB, KDR,
and FLT4 appear as the top-studied kinase targets, each having
more than 120 active compounds (Figure S6A). Among mutated
kinases, variants of BRAF and ABL1 emerge in the top tier,
being targeted by more than 100 active compounds each
(Figure S6B). Having access to both mutant and wild-typebioactivities enables mining compounds with a selective activity
against a particular disease- or resistance-related kinase
mutation.
As a case example, we focused on BCR-ABL1 fusion gene,
given its importance in precision medicine for chronic myeloid
leukemia (CML). Specifically, we took all the compounds in
DTC that have reported potencies against ABL1 wild-type,
BCR-ABL1(T315I), and Aurora B kinase, since inhibition of
aurora kinases has turned out to be a dose-limiting toxicity-
inducing off-target effect of BCR-ABL1(T315I) inhibitors (Gold-
enson and Crispino, 2015), and clustered them based on their
structural similarities (Figure 3A). Such a target-specific tree
provided enhanced information about themutation-selective ac-
tivities across a wide panel of approved and investigational com-
pounds. For example, a VEGFR inhibitor axitinib was recently
identified as a potent and selective BCR-ABL(T315I) inhibitor
(Pemovska et al., 2015), and it is currently undergoing a clinical
trial for CML (NCT02782403). Notably, compounds structurally
similar to axitinib, including TAE-684 and KW-2449, also showed
a strong potential to be repositioned as BCR-ABL1(T315I) inhib-
itors (highlighted in Figure 3A). Using a cell-based assay (Fig-
ure 3B), we confirmed that KW-2449, originally developed as
an FLT3 inhibitor, is indeed active toward BCR-ABL1(T315I).Cell Chemical Biology 25, 224–229, February 15, 2018 227
However, we could not replicate the TAE-684 bioactivities,
perhaps due to differing assay format compared with the original
data source. This example shows how DTC data enable map-
ping of potential compound activities but also highlights the
importance of cell-based target validation, ideally using multiple
experimental assays, before entering into expensive and long
drug development and clinical testing phases.
An Invitation to Join the Collaborative Effort to Reuse
and Extend Bioactivity Research Data
The major contributions of DTC as a drug discovery tool are the
mBAO annotation and the crowd-sourcing web platform, which
make it possible to utilize community power to enable deeper-
level annotation of an extensive set of bioactivity assays, a pro-
cess that is beyond the scope of any individual institute or group
if working alone. The key to enable such a collaborative effort re-
lies on effective communication and advertising, emphasizing
the transparency, open-access, and ease-of-use of the DTC
platform. The mBAO annotation system will be improved based
on the emerging needs from the community, yet keeping it sim-
ple enough to allow for large-scale annotations. With an
increasing number of data providers and curators joining this
effort, we envision that the bioactivity data from public data-
bases and newly published studies will be continuously anno-
tated (Figure 1).
In the next phase, the fully annotated data will be cross-
compared to reach a consensus view through community knowl-
edge and evidence-based integration approaches (Knapp et al.,
2013; Tang et al., 2014; Wang et al., 2016). We expect there will
be a number of tools built on the DTC data by us and others that
will provide added value from the bioactivity data, similar to the
C-SPADE tool used in the present study for polypharmacological
visualization (Ravikumar et al., 2017). In the long term, DTC will
provide a sustainable open-access resource for many exciting
applications, such as extending the space of the ‘‘druggable’’
cancer genome, not only for kinases but also for other target
families including GPCRs, ion channels, and nuclear receptors.
Comprehensive target selectivity profiles are also critical for
the ongoing precision oncology efforts that use patient-specific
mutation panels for tailoring targeted therapies (Dienstmann
et al., 2015; Chakradhar, 2016; Griffith et al., 2017).
SIGNIFICANCE
We have initiated Drug Target Commons (DTC) as a commu-
nity-based crowd-sourcing platform designed to improve
the reuse and consensus of compound-target bioactivity
profiles. DTC implements an open environment to collec-
tively curate, annotate, and integrate drug-target bioactivity
data from literature and other resources. In this report, we
demonstrated the added value and benefits of the DTC plat-
form for application use cases relevant for drug discovery
and repurposing applications. The deep-level expert cura-
tion and annotation as well as improved consensus on po-
tency, selectivity, and therapeutic relevance of compounds
are expected to greatly benefit many biological discovery,
phenotypic profiling, and target deconvolution efforts in
the future. To achieve the greatest impact, we invite
chemical biologists, medicinal chemists, and computational228 Cell Chemical Biology 25, 224–229, February 15, 2018biologists to join the community-driven data harmonization
effort. As a return, all the curated data are freely available at
http://drugtargetcommons.fimm.fi.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
d METHOD DETAILSB Cell Line Assays
B Potent Bioactivities
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITYSUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and two data files
and can be found with this article online at https://doi.org/10.1016/j.chembiol.
2017.11.009.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
Axitinib LC Laboratories Cat#A-1107
KW-2449 Selleck Chemicals Cat#S2158
TAE684 MedChemExpress Cat#HY-10192
Mouse IL-3 Recombinant Protein eBioscience Cat#14-8031-62
Deposited Data
Bioactivity data and assay annotations DTC website https://drugtargetcommons.fimm.fi/
Experimental Models: Cell Lines
Mouse: Ba/F3 parental cells
(IL-3 dependent)
The Leibniz Institute DSMZ -GermanCollection
of Microorganisms and Cell Cultures GmbH
(DSMZ)
RRID:CVCL_0161
Mouse: Ba/F3 cells stably expressing
BCR-ABL1
Tea Pemovska, (Pemovska et al., 2015) NA
Mouse: Ba/F3 cells stably expressing
BCR-ABL1 (T315I)
This paper NA
Human: 90.74 (CRL-11654) American Type Culture Collection (ATCC) Cat#CRL-11654; RRID:CVCL_6361
Recombinant DNA
pMIG-BCR-ABL1 plasmid Prof. Dr. Nikolas von Bubnoff, University
Medical Center Freiburg, Freiburg, Germany
NA
pMIG-BCR-ABL1 (T315I) plasmid Prof. Dr. Nikolas von Bubnoff, University
Medical Center Freiburg, Freiburg, Germany
NA
Software and Algorithms
GraphPad Prism 7 GraphPad Prism Software, Inc. https://www.graphpad.com/
Backend development technology:
Python 3.4
DTC website https://www.python.org/download/
releases/3.4.0/
Frontend technology: Jquery 1.11.1,
JavaScript
DTC website https://blog.jquery.com/2014/05/01/
jquery-1-11-1-and-2-1-1-released/
Postgresql 9 DTC database https://www.postgresql.org/download/
Figures: MATLAB, R , Python This paper https://www.mathworks.com/products/
new_products/release2016a.html
https://www.rstudio.com/
https://www.python.org/download/
releases/3.4.0/
C-SPADE Figure 3 of this paper http://cspade.fimm.fi
mBAO (micro bioassay ontology) protocol This paper NACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tero
Aittokallio (tero.aittokallio@helsinki.fi)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ba/F3 cells stably expressing BCR-ABL1 or BCR-ABL1 T315I were cultured in RPMI 1640 supplemented with 10% fetal bovine
serum (FBS), L-glutamine and penicillin-streptomycin. For Ba/F3 parental cells (sex unknown), mouse recombinant interleukin-3
(IL-3; eBioscience) was added to the growth medium at a concentration of 10 ng/ml. The human virus-packaging cell line CRL-
11654 (female) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% FBS and 1% penicillin-streptomycin.
All cell lines were kept in 5% CO2 at 37
C. Ba/F3 parental cells (DSMZ) and CRL-11654 (ATCC) were purchased directly from their
sources but were not authenticated.e1 Cell Chemical Biology 25, 224–229.e1–e2, February 15, 2018
METHOD DETAILS
Cell Line Assays
The Ba/F3 murine IL-3-dependent pro-B cell line was used to test kinase activity in a manner similar to previous studies (Warmuth
et al., 2007). Ba/F3 cells stably expressing BCR-ABL1 were provided by Tea Pemovska and made as described here. Briefly, Ba/F3
cells stably expressing pMIG-BCR-ABL1 and pMIG-BCR-ABL1(T315I) plasmids made by infection with replication-incompetent ret-
roviruses containing coding sequences for BCR-ABL1 and BCR-ABL1(T315I) collected after transfection of a virus-packaging cell
line (CRL-11654, ATCC). 4 days post-infection, a stable expressing population was selected by removal of IL-3 for approximately
10 days. Ba/F3 cells stably expressing BCR-ABL1 or BCR-ABL1 (T315I) were then treated with a range of concentrations of axitinib,
KW-2449 and TAE-684. Cell viability was detected by CellTiter-Glo Luminescent Cell Viability Assay (Promega) in a 384-well plate
format. Luminescence was measured using a PHERAstar FS microplate reader (BMG Labtech), and half-maximal inhibitory concen-
tration (IC50) was calculated (GraphPad Prism) to assess sensitivity of cell lines to the tested compounds. All assays were repeated at
least three times, with consistent results.
Implementation Issues
The DTC platform was implemented to support a community-driven crowdsourcing effort to improve the consensus and use of bio-
logical target profiles of drugs and chemical tools (Figure 1). Common annotation terms are critical for standardizing biological ex-
periments. To facilitate the data curation process, we implemented mBAO assay annotation that standardizes the description of
target profiling experiments in terms of the assay type and format, endpoint type, detection technology, and other key determinants
of the bioactivity readout (Figure S1). The web-based graphical user interface (GUI) enables end-users to search, view and download
existing or community-annotated bioactivity data using a variety of compound, target or publication identifiers (see Data S1 for the
user manual). Using the GUI, the expert users may also submit suggestions to edit or add new bioactivity data, as well as take part in
the mBAO bioassay annotation and data curation process (see Data S2 for the glossary of annotation terms). Through the freely
accessible DTC platform, the users cannot only upload new bioactivity data from their own experiments or literature, but can also
participate in the process of data annotation, integration and quality-control, together with the committed domain experts. Such
an open environment ensures that the experimental data points will be maximally curated, evaluated, and cross-checked before be-
ing deposited into the open DTC database for the downstream analyses.
Potent Bioactivities
We defined ’potent targets’ and ’potent inhibitors’ based on specific bioactivity cut-offs for the four most popular bioactivity types
(Kd, Ki, IC50 and activity):%100 nM for the dose-responsemeasurements (Kd, Ki or IC50) in biochemical assays, and%1000 nM for the
dose-responsemeasurements (Kd, Ki or IC50) in cell-based and other assay types. For the activity measurements (activity%, residual
activity% or %inhibition), often resulting from assays with single or a few concentration points only, we defined a rather stringent
threshold: %10% for the test concentration %1000 nM and %20% for test concentration of %500 nM in biochemical assays,
and%50% for the test concentration%1000 nM and%10% for the test concentration%10000 nM in the cell-based assays. In cases
where there weremultiple bioactivity values for a compound-target pair, originating from different studies or other data resources, we
took median bioactivity.
QUANTIFICATION AND STATISTICAL ANALYSIS
No statistical analysis was performed on the cell line assay replicates.
DATA AND SOFTWARE AVAILABILITY
All the bioactivity data points and annotations are freely available using application-programming interface (API) or direct download
(CSV file) through DTC website: http://drugtargetcommons.fimm.fi (Download tab). See also https://drugtargetcommons.fimm.fi/
userguide/ and https://drugtargetcommons.fimm.fi/glossary/. Details about source publications for fully annotated bioactivities
are provided in Table S3.Cell Chemical Biology 25, 224–229.e1–e2, February 15, 2018 e2
